[{"orgOrder":0,"company":"Undisclosed","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Nika Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Vinpocetine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Undisclosed

                          Country arrow
                          BOS Manchester
                          Not Confirmed

                          Undisclosed

                          Country arrow
                          BOS Manchester
                          Not Confirmed

                          Details : The acquisition includes technologies for producing generics as tablet, Vinpocetine, Menthyl Valerate, and Metamizole Sodium, and a dietary supplement, Tribulus Terrestris Herba Extractum Siccum.

                          Brand Name : Vinpocetine-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 15, 2024

                          Lead Product(s) : Vinpocetine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Nika Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank